|
AVEO PHARMA LIMITED
REGISTERED NUMBER: 06456614
BALANCE SHEET
AS AT 31 DECEMBER 2025
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debtors: amounts falling due within one year
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets less current liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the year ended 31 December 2025 the Company was entitled to exemption from audit under section 480 of the Companies Act 2006.
Members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.
The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.
The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.
The financial statements were approved and authorised for issue by the board and were signed on its behalf by:
................................................
Danielle Holland
|
|
|
|
|
|
|
The notes on page 2 form part of these financial statements.
|
|
AVEO PHARMA LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
AVEO Pharma Limited (the Company) is a company incorporated in the United Kingdom under the Companies Act.
The Company is a private company limited by shares and is registered in England and Wales.The address of the Company’s registered office is 5th Floor Halo, Counterslip, Bristol, BS1 6AJ.
The Company’s functional and presentational currency is pounds sterling (GBP) and the financial statements are rounded to the nearest pound (£).
2.Accounting policies
|
|
|
Basis of preparation of financial statements
|
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.
|
|
|
|
|
|
|
Amounts owed by group undertakings
|
|
|
|
|
|
|
|
Other reserves
Other reserves represents the amount relating to additional paid in capital which exceeds the nominal value of the shares and represents the capital contribution.
Profit and loss account
Profit and loss account represents the cumulative profits or losses net of dividends paid and other adjustments.
The parent company is AVEO Pharmaceuticals, Inc. (registered and incorporated in the United States of America). The largest and smallest group in which the results of the company are consolidated is that headed by AVEO Pharmaceuticals Inc. The consolidated accounts of this company are available to the public and may be obtained from www.aveooncology.com. The ultimate parent company is LG Chem, Ltd. (incorporated in the Republic of Korea).
The directors of the company do not consider there to be an ultimate controlling party.
|